Table 3.

Prevalence of ANCA detected by anti-IgG and anti-IgA secondary antibodies in patients with primary sclerosing cholangitis (with IBD/without IBD) and autoimmune hepatitis

	Primary sclerosing cholangitis
	total (n = 35)	with IBD (n = 21)	without IBD (n = 14)	Autoimmune hepatitis (n = 40)
IgA ANCA only	1/35 (3%)	1/21 (5%)	0/14 (0%)	2/40 (5%)
IgG ANCA only	21/35 (60%)	11/21 (52%)	10/14 (71%)	16/40 (40%)
IgA and IgG ANCA	6/35 (17%)	4/21 (19%)	2/14 (14%)	18/40 (45%)
Total ANCA positive	28/35 (80%)	16/21 (76%)	12/14 (86%)	36/40 (90%)
Total ANCA negative	7/35 (20%)	5/21 (24%)	2/14 (14%)	4/40 (10%)

ANCA, antineutrophil cytoplasmic antibody; IBD, inflammatory bowel disease.